头对头礼来“匹妥布替尼”!百济神州 BTK 降解剂又启动一项 Ⅲ 期临床

Insight数据库
May 16, 2025

5 月 15 日,Clinicaltrials.gov 网站显示,百济神州启动一项 BTK 降解剂 BGB-16673 的 Ⅲ 期临床(NCT06973187),旨在评估BGB-16673与匹妥布替尼在复发/难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤成人患者(CLL/SLL)中的安全性和有效性。截图来源:Clinicaltrials.gov 官网BGB-16673 是百济神州开发的一种口服、靶向 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10